Efficacy and safety of camrelizumab (a PD‑1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non‑small cell lung cancer

Hou,Xinlei; Shi,Xueliang; Luo,Jie

doi:10.3892/ol.2022.13336

Efficacy and safety of camrelizumab (a PD‑1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non‑small cell lung cancer

Authors:
- Xinlei Hou
- Xueliang Shi
- Jie Luo
View Affiliations

Affiliations: Department of Thoracic Surgery, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163001, P.R. China, Department of Ophthalmology, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163001, P.R. China
Published online on: May 17, 2022 https://doi.org/10.3892/ol.2022.13336
Article Number: 215
Copyright: © Hou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Camrelizumab is a novel programmed cell death protein 1 (PD‑1) inhibitor developed in China that exhibits good efficacy in several advanced cancer types, including non‑small cell lung cancer (NSCLC); however, its utility as a neoadjuvant regimen in NSCLC remains unclear. Thus, the present study aimed to explore the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced NSCLC. A total of 56 patients with stage IIIA/IIIB resectable NSCLC were analyzed in the present prospective observational study. Amongst the cohort, 31 patients underwent neoadjuvant camrelizumab (200 mg every 2 weeks) plus paclitaxel and carboplatin (PC) chemotherapy, while another 25 cases underwent neoadjuvant PC chemotherapy alone. The pathological response, disease‑free survival (DFS) time, overall survival (OS) time and adverse events (AEs) were analyzed. The complete pathological response (25.8 vs. 8.3%; P=0.159) and major pathological response (MPR) (61.3 vs. 37.5%; P=0.080) rates were higher in the camrelizumab plus PC group compared with the findings in the PC group, although the results were not statistically significant. DFS time was significantly prolonged in the camrelizumab plus PC group compared with that in the PC group (P=0.030); however, there was no difference in OS time between these two groups (P=0.251). Following adjustment by multivariate analysis, the camrelizumab plus PC regimen versus the PC regimen alone was independently associated with higher MPR [odds ratio, 5.216; 95% confidence interval (CI), 1.178‑23.086; P=0.030], and favorable DFS [hazard ratio (HR), 0.055; 95% CI, 0.007‑0.442; P=0.006] and OS (HR, 0.025; 95% CI, 0.002‑0.416; P=0.010) times. The most common AEs of the neoadjuvant camrelizumab plus PC regimen were alopecia (51.6%), nausea and vomiting (45.2%), anemia (41.9%) and fatigue (41.9%), the majority of which occurred in patients with grade 1‑2 disease. The present results indicated that neoadjuvant camrelizumab plus PC chemotherapy exhibited a superior pathological response and survival profile to PC chemotherapy alone, and was well tolerated in patients with locally advanced NSCLC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Clark SB and Alsubait S: Non Small Cell Lung Cancer. StatPearls. Treasure Island; FL: 2021
3	Ikeda N: Updates on minimally invasive surgery in non-small cell lung cancer. Curr Treat Options Oncol. 20:162019. View Article : Google Scholar
4	Alexander M, Kim SY and Cheng H: Update 2020: Management of non-small cell lung cancer. Lung. 198:897–907. 2020. View Article : Google Scholar : PubMed/NCBI
5	Jazieh AR, Zeitouni M, Alghamdi M, Alrujaib M, Lotfi S, Daff SA, Alomair A, Alshehri S, Alhusaini H, Allehebi A, et al: Management guidelines for stage III non-small cell lung cancer. Crit Rev Oncol Hematol. 157:1031442021. View Article : Google Scholar
6	Patane AK: Minimal invasive surgery in locally advanced N2 non-small cell lung cancer. Transl Lung Cancer Res. 10:519–528. 2021. View Article : Google Scholar : PubMed/NCBI
7	Passiglia F, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, Franchina T, Malapelle U, Menis J, Passaro A, Pilotto S, et al: Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. Crit Rev Oncol Hematol. 148:1028622020. View Article : Google Scholar
8	Ren S, Xu A, Lin Y, Camidge DR, Maio MD, Califano R, Hida T, Rossi A, Guibert N, Zhu C and Shen J: A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: Past, present and future. Transl Lung Cancer Res. 10:3264–3275. 2021. View Article : Google Scholar : PubMed/NCBI
9	Xiong L, Lou Y, Bai H, Li R, Xia J, Fang W, Zhang J, Zhang HH, Lizaso A, Li B, et al: Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. J Int Med Res. 48:3000605198872752020. View Article : Google Scholar : PubMed/NCBI
10	Zhang C, Li SL, Nie Q, Dong S, Shao Y, Yang XN, Wu YL, Yang Y and Zhong WZ: Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement. J Thorac Oncol. 14:726–731. 2019. View Article : Google Scholar
11	Zhao S, Zhu S, Lei X, Xu D, Shi T, Chen Q, Ren F, Chen G, Huang D and Xu S: Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report. Thorac Cancer. 12:2815–2818. 2021. View Article : Google Scholar : PubMed/NCBI
12	Markham A and Keam SJ: Camrelizumab: First global approval. Drugs. 79:1355–1361. 2019. View Article : Google Scholar : PubMed/NCBI
13	Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, et al: Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA. 326:916–925. 2021. View Article : Google Scholar : PubMed/NCBI
14	Huang Y, Zhang Z, Liao W, Hu K and Wang Z: Combination of sorafenib, camrelizumab, transcatheter arterial chemoembolization, and stereotactic body radiation therapy as a novel downstaging strategy in advanced hepatocellular carcinoma with portal vein tumor thrombus: A case series study. Front Oncol. 11:6503942021. View Article : Google Scholar
15	Qu YY, Zhang HL, Guo H, Luo H, Zou Q, Xing N, Xia S, Sun Z, Zhang X, He C, et al: Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: Data from an open-label, multicenter phase II basket study. Clin Cancer Res. 27:5838–5846. 2021. View Article : Google Scholar : PubMed/NCBI
16	Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, et al: Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 9:305–314. 2021. View Article : Google Scholar : PubMed/NCBI
17	Zhou N, Jiang M, Li T, Zhu J, Liu K, Hou H and Zhang X: Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. Lung Cancer. 160:111–117. 2021. View Article : Google Scholar : PubMed/NCBI
18	Wang P, Fang X, Yin T, Tian H, Yu J and Teng F: Efficacy and safety of anti-pd-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study. Front Oncol. 11:6281242021. View Article : Google Scholar
19	Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, Kennedy C, Krasnik M, Peake M, Shemanski L, et al: The IASLC lung cancer staging project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 12:1109–1121. 2017. View Article : Google Scholar
20	Mischel AM and Rosielle DA: Eastern cooperative oncology group performance status #434. J Palliat Med. 25:508–510. 2022. View Article : Google Scholar : PubMed/NCBI
21	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, et al: Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 7:825–832. 2012. View Article : Google Scholar
23	Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, et al: IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 15:709–740. 2020. View Article : Google Scholar
24	Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0. J Am Acad Dermatol. 67:1025–1039. 2012. View Article : Google Scholar
25	Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, et al: Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21:786–795. 2020. View Article : Google Scholar
26	Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, et al: Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 30:1653–1659. 2019. View Article : Google Scholar
27	Wei F, Huang Q, He J, Luo L and Zeng Y: Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: A short-term prognostic study. Cancer Manag Res. 13:4233–4240. 2021. View Article : Google Scholar : PubMed/NCBI
28	Yang G, Su X, Yang H, Luo G, Gao C, Zheng Y, Xie W, Huang M, Bei T, Bai Y, et al: Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma. Ann Transl Med. 9:12542021. View Article : Google Scholar : PubMed/NCBI
29	Wu Z, Zheng Q, Chen H, Xiang J, Hu H, Li H, Pan Y, Peng Y, Yao X, Liu P, et al: Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis. 13:3518–3528. 2021. View Article : Google Scholar : PubMed/NCBI
30	Qiao ZY, Zhang ZJ, Lv ZC, Tong H, Xi ZF, Wu HX, Chen XS, Xia L, Feng H, Zhang JJ and Xia Q: Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: A cohort study and literature review. Front Immunol. 12:6534372021. View Article : Google Scholar
31	Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, Carpeño JD, et al: Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar
32	Chen T, Ning J, Campisi A, Dell'Amore A, Ciarrocchi AP, Li Z, Song L, Huang J, Yang Y, Stella F and Luo Q: Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC: A retrospective study. Ann Thorac Surg. 113:993–999. 2021. View Article : Google Scholar : PubMed/NCBI
33	Wang J, Li J, Cai L, Chen S and Jiang Y: The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer. Ann Transl Med. 9:4862021. View Article : Google Scholar : PubMed/NCBI
34	Chen Z, Lu X and Koral K: The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 14:1017–1024. 2020. View Article : Google Scholar
35	Yang C, Xu C, Li X and Zhang Y, Zhang S, Zhang T and Zhang Y: Could camrelizumab plus chemotherapy improve clinical outcomes in advanced malignancy? A systematic review and network meta-analysis. Front Oncol. 11:7001652021. View Article : Google Scholar